Pharmaceutical Research Associates Group B.V.
- Address
- Van Swietenlaan 6, 9728 NZ Groningen, The Netherlands
Oncology Research
The site conducts extensive studies in Neoplasms, focusing on cancers such as breast and lung that affect a broad patient population. Trials aim to evaluate new therapeutic agents and improve treatment outcomes for advanced disease stages.
- HER2‑negative breast cancer
- Triple‑negative breast cancer
- Advanced non‑small cell lung cancer
- Castration‑resistant prostate cancer
- Follicular lymphoma
- Metastatic breast cancer
- Small cell lung cancer
Pharmaceutical Research Associates Group B.V. leverages its expertise to advance oncology drug development and support patients in Groningen and beyond.
Neurology and Neurodegeneration
Research at the centre addresses neurodegenerative disorders by testing innovative compounds and diagnostic tools for diseases that impair motor and cognitive function. The goal is to discover treatments that slow progression and improve quality of life.
- Alzheimer’s Disease
- Parkinson’s disease
- Amyotrophic Lateral Sclerosis
- Multiple sclerosis
- Parkinsonian syndromes
Ongoing studies explore disease‑modifying strategies and biomarkers to better understand these conditions.
Metabolic and Cardiovascular Disorders
The programme targets metabolic and cardiovascular diseases, evaluating novel agents that address glucose regulation, weight management, and heart function. Trials are designed to assess safety and therapeutic benefit in at‑risk populations.
- Type 2 Diabetes
- Obesity and overweight
- Chronic heart failure
- Cardiometabolic diseases with inflammatory component
- Cholestatic liver disease
- Chronic kidney disease
Findings support the development of integrated therapies for patients with combined metabolic and cardiac conditions.
Infectious Diseases and Immune Disorders
Studies focus on infectious and immune‑mediated conditions, aiming to improve treatment options for bacterial infections, parasitic diseases, and rare immune syndromes. Research includes evaluating drug‑drug interactions and novel antimicrobial agents.
- Community‑acquired bacterial pneumonia
- Severe Gram‑negative bacterial infections
- Malaria
- Hereditary angioedema
- Bacterial infection
The site’s work contributes to better therapeutic strategies and resistance management.
Rare and Genetic Conditions
The centre addresses rare and genetic diseases by testing targeted therapies and advancing understanding of disease mechanisms. Clinical investigations seek to provide options where few exist.
- Autosomal dominant polycystic kidney disease
- Cryopyrin associated periodic syndrome
- Glycosphingolipid lysosomal storage disorders
- Primary sclerosing cholangitis
- Transthyretin amyloid cardiomyopathy
Collaborative efforts aim to translate genetic insights into effective treatments.
Diagnostic and Imaging Advances
Research includes development of advanced diagnostic and imaging techniques to enhance disease detection and monitoring. Projects evaluate contrast agents, radiolabeled compounds, and pharmacokinetic profiling tools.
- Contrast‑enhanced MRI for head and neck
- PET imaging agents for oncology
- Mass balance studies of radiolabeled drugs
- Pharmacokinetic and bioavailability assessments
- Drug‑drug interaction evaluations
These initiatives support more accurate diagnosis and personalized treatment planning.
Mental Health Research
The site conducts trials in mental health and psychiatry, focusing on new therapeutics for mood disorders and behavioral conditions. Studies assess efficacy, safety, and impact on daily functioning.
- Major Depressive Disorder
- Behavioral disciplines and activities
- Mental disorders
- Psychiatric assessments
Efforts aim to expand therapeutic options and improve outcomes for patients with psychiatric illnesses.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 6 of 9 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1F. Hoffmann-La Roche AG4active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG15trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pharmaceutical Research Associates Group B.V.
lock Showing 1 of 117 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pharmacokinetic Comparison of Two Oral Formulations of Petadeferitrin in Healthy Volunteers | Pharmacosmos A/S | Phase I | Not Yet Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL | 1 | Unknown | 2023-07-13 | 2023-07-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.